Drug Database · Clinicians

Desloratadine

Brands (22) Deslogen, Aerius, Allergon…Show all

US brand (reference label): Clarinex; not a Philippine-registered brand.

Histamine-1 Receptor Antagonist (Histamine H1 Receptor Antagonists) US FDA class
Antihistamine for systemic use; Other antihistamine for systemic use PH FDA category

Rx · Prescription drug31 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID c671342e-69a2-4ca5-abc2-8166ed4240d4, version date May 17, 2025 (Clarinex · Organon LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older.
  • Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older.
  • Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE CLARINEX is a histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 2 years of age and older. (1.1) Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 6 months of age and older. (1.2) Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 6 months of age and older.

(1.3) 1.1 Seasonal Allergic Rhinitis CLARINEX ® is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. 1.2 Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. 1.3 Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older.

Contraindications

4 CONTRAINDICATIONS CLARINEX Tablets, RediTabs, and Oral Solution are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see Warnings and Precautions (5.1) and Adverse Reactions (6.2)]. Hypersensitivity (4, 6.2)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Although the oral solution and the orally disintegrating tablet formulation of desloratadine may be available in the marketplace, CLARINEX ® Oral Solution and CLARINEX ® RediTabs ® Tablets are no longer marketed. CLARINEX Tablets, Oral Solution, or RediTabs Tablets may be taken without regard to meals. Place CLARINEX (desloratadine) RediTabs Tablets on the tongue and allow to disintegrate before swallowing.

Tablet disintegration occurs rapidly. Administer with or without water. Take tablet immediately after opening the blister. The age-appropriate dose of CLARINEX Oral Solution should be administered with a commercially available measuring dropper or syringe that is calibrated to deliver 2 mL and 2.5 mL (½ teaspoon). Dosage (by age): Adults and Adolescents 12 Years of Age and Over: CLARINEX Tablets - one 5 mg tablet once daily or CLARINEX RediTabs Tablets - one 5 mg tablet once daily or CLARINEX Oral Solution - 2 teaspoonfuls (5 mg in 10 mL) once daily (2) Children 6 to 11 Years of Age: CLARINEX Oral Solution - 1 teaspoonful (2.5 mg in 5 mL) once daily or CLARINEX RediTabs Tablets - one 2.5 mg tablet once daily (2) Children 12 Months to 5 Years of Age: CLARINEX Oral Solution - ½ teaspoonful (1.25 mg in 2.5 mL) once daily (2) Children 6 to 11 Months of Age: CLARINEX Oral Solution - 2 mL (1 mg) once daily (2)

2.1 Adults and Adolescents 12 Years of Age and Over

2.1 Adults and Adolescents 12 Years of Age and Over The recommended dose of CLARINEX Tablets or CLARINEX RediTabs Tablets is one 5-mg tablet once daily. The recommended dose of CLARINEX Oral Solution is 2 teaspoonfuls (5 mg in 10 mL) once daily.

2.2 Children 6 to 11 Years of Age

2.2 Children 6 to 11 Years of Age The recommended dose of CLARINEX Oral Solution is 1 teaspoonful (2.5 mg in 5 mL) once daily. The recommended dose of CLARINEX RediTabs Tablets is one 2.5-mg tablet once daily.

2.3 Children 12 Months to 5 Years of Age

2.3 Children 12 Months to 5 Years of Age The recommended dose of CLARINEX Oral Solution is ½ teaspoonful (1.25 mg in 2.5 mL) once daily.

2.4 Children 6 to 11 Months of Age

2.4 Children 6 to 11 Months of Age The recommended dose of CLARINEX Oral Solution is 2 mL (1 mg) once daily.

2.5 Adults with Hepatic or Renal Impairment

2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [see Clinical Pharmacology (12.3)].

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration, use in specific populations)

2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [see Clinical Pharmacology (12.3)].

8.6 Renal Impairment Dosage adjustment for patients with renal impairment is recommended [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Hepatic impairment

8.7 Hepatic Impairment Dosage adjustment for patients with hepatic impairment is recommended [see Dosage and Administration (2.5) and Clinical Pharmacology (12.3)].

2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use The recommended dose of CLARINEX Oral Solution in the pediatric population is based on cross-study comparison of the plasma concentration of CLARINEX in adults and pediatric subjects. The safety of CLARINEX Oral Solution has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies.

Since the course of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria and the effects of CLARINEX are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients. The effectiveness of CLARINEX Oral Solution in these age groups is supported by evidence from adequate and well-controlled studies of CLARINEX Tablets in adults.

The safety and effectiveness of CLARINEX Tablets or CLARINEX Oral Solution have not been demonstrated in pediatric patients less than 6 months of age. [See Clinical Pharmacology (12.3).] The CLARINEX RediTabs 2.5-mg tablet has not been evaluated in pediatric patients. Bioequivalence of the CLARINEX RediTabs Tablet and the previously marketed RediTabs Tablet was established in adults.

In conjunction with the dose-finding studies in pediatrics described, the pharmacokinetic data for CLARINEX RediTabs supports the use of the 2.5-mg dose strength in pediatric patients 6 to 11 years of age.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. [See Clinical Pharmacology (12.3).]

Dosage forms

Philippines

  • Film-coated tablet: 5 mg
  • Syrup: 2.5 mg/5 mL
  • Tablet: 5 mg

Registered products in the Philippines

31 products registered with the Food and Drug Administration (FDA) Philippines list Desloratadine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Desloratidine (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products31
Philippine FDA-registered products for Desloratadine
Package insert
AERIUSDesloratadine
2.5 mg/5 mL SyrupPh. Eur Type III Amber glass bottle with a tamper-evident child-resistant polypropylene cap with laminated liner with polyethylene as the product contact surface and a polyethylene break ring x 60 mL (Box of 1’s)
Rx
Organon Heist bvBelgium
Importer: Organon (Philippines) Incorporated
DRP-8946
Jul 8, 2031
AeriusDesloratadine
5 mg TabletPVC-PCTFE/Aluminum Foil x 10's (Box of 100's); PVC-PCTFE/Aluminum Foil x 2's (Box of 2's as Physician's Sample); PVC-PCTFE/Aluminum Foil x 10's (Box of 10's as Physician's Sample)
Rx
Organon Heist b.vBelgium
Importer: Organon (Philippines) Incorporated
DR-XY39221
Mar 25, 2031
AizeneDesloratadine
2.5 mg/5 mL Syrup (Mixed Fruit Flavor)PET amber bottle with cap x 60 mL (Box of 1's)
Rx
Gracure Pharmaceuticals Ltd.India
Despina Pharma Inc.
DRP-15449
Jul 12, 2029
AlesydDesloratadine
2.5 mg / 5mL SyrupUSP Type III Amber Glass Bottle with 20 mm foam-lined PP aluminum cap x 60 mL (Box of 1's)
Rx
Sydenham Laboratories, Inc.Philippines
—
DRP-12904
Oct 27, 2027
AllergonDesloratadine
5 mg Film-Coated TabletAlu/Alu Blister Pack x 6's (Box of 12's)
Rx
Hainan Poly Pharm. Co., Ltd.China
AMB HK Enterprises Inc.
DR-XY44123
Feb 2, 2028
AllergonDesloratadine
5 mg Film-Coated TabletAlu/Alu Blister Pack x 6's (Box of 12's)
Rx
Hainan Poly Pharm. Co., Ltd.China
FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc.
DRP-15225
Feb 2, 2028
AroledDesloratadine
2.5 mg/5 mL Syrup (Orange Flavor)PET Bottle x 60 ml (Box of 1’s)
Rx
Stallion Laboratories Pvt. Ltd.India
D&G PharmaImporter: Ambica International Corporation
DRP-3743-01
May 14, 2032
AroledDesloratadine
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's
Rx
Stallion Laboratories Pvt. Ltd.India
D & G PharmaImporter: Ambica International Corporation
DRP-4290-02
Mar 8, 2028
DeslodineDesloratadine
2.5 mg/5 mL Syrup (Orange Flavor)60 mL PET Bottle (Box of 1's)
Rx
Stallion Laboratories Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation
DRP-3743
May 14, 2032
DeslodineDesloratadine
5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Multicare Pharmaceuticals Phils. Inc.Importer: Ambica International Corporation
DRP-4290-01
Mar 8, 2028
DeslogenDesloratadine
2.5 mg/5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DR-XY42707
Oct 2, 2028
DeslogenDesloratadine
2.5 mg/5 mL SyrupAmber Glass Bottle x 60 mL (Box of 1's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-15173
Oct 2, 2028
DeslogenDesloratadine
5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Innogen Pharmaceuticals, Inc.
DRP-7291
Mar 12, 2031
DeslorastalDesloratadine
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's
Rx
Stallion Laboratories Pvt. Ltd.India
Detoxicare Philippines, Inc.Importer: Ambica International Corporation
DRP-4290
Mar 8, 2028
DeslotrisDesloratadine
5 mg Film-Coated TabletAlu-Alu Blister Pack X 10's (Box of 30's)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-18174
May 21, 2031
DestacureDesloratadine
2.5 mg/5mL SyrupPET amber-colored bottle with white ROPP cap x 60 mL (Box of 1's)
Rx
Gracure Pharmaceutical Ltd.India
Aglobal Care, Inc.
DRP-15593
Aug 7, 2029
DestadineDesloratidineVariant spelling
2.5mg/5ml SyrupAmber PET bottle x 60 mL (Box of 1's)
Rx
Gracure Pharmaceutical Ltd.India
Healol Pharma Corporation
DRP-16754
Jul 11, 2030
DestavellDesloratadine
5 mg Film-Coated TabletAluminum/EAA Foil Strip x 10's (Box of 30's)
Rx
PT. Novell Pharmaceutical LaboratoriesGunung Putri Bogor 16962 - Indonesia
Prosweal Healthcare Inc.
DR-XY47619
Dec 21, 2031
DezlotinDesloratadine
5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's)
Rx
Aurochem Pharmaceuticals (India) Pvt., Ltd.India
Endure Medical, Inc.
DR-XY43831
Oct 27, 2029
DonzelpinDesloratadine
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-10787
Nov 19, 2031
Genodes-5Desloratadine
5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
Rx
Sydler Remedies Pvt. LimitedIndia
Medethix, Inc.
DRP-3757
Oct 25, 2029
Histalor-DDesloratadine
5 mg Film-Coated TabletAlu/PVDC Film Blister Pack x 10 (Box of 100's)
Rx
Sai Mirra Innopharm Pvt. Ltd.India
Eon Pharmatek Inc.
DR-XY47540
Nov 18, 2031
KiddiesDesloratadine
2.5 mg/5 mL SyrupAmber PET Bottle x 60 mL (Box of 1's)
Rx
Stallion Laboratories Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-4707
Sep 13, 2028
Lora-DDesloratadine
5 mg Film-Coated TabletPVC/Alu Blister Pack x 10's (Box of 30's)
Rx
Ind-Swift LimitedIndia
Ritemed Phils., Inc.
DR-XY42644
Sep 17, 2036
Lorahist 5Desloratadine
5 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's)
Rx
Unison Laboratories Co., Ltd.Thailand
Justright Healthcare Inc.
DR-XY49812
Sep 29, 2031
NoneDesloratadine
5 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's)
Rx
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-4290-03
Mar 8, 2028
SedlorDesloratadine
5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
Rx
Medchem International, Inc.India
Pharma-Surrey International, Inc.
DRP-3343
Nov 2, 2028
Sylergy NeoDesloratadine
2.5 mg / 5mL SyrupUSP Type III Amber Glass Bottle with 20 mm foam-lined PP aluminum cap x 60 mL (Box of 1's)
Rx
Sydenham Laboratories, Inc.Philippines
Sydenham Pharmaceuticals, Inc.
DRP-12903
Oct 27, 2027
UnbrandedDesloratadine
2.5 mg/5 mL Syrup (Orange Flavor)60 mL PET Bottle (Box of 1’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-3743-02
May 14, 2032
UnbrandedDesloratadine
5 mg TabletAlu-Alu Blister Strip x 10's (Box of 100's)
Rx
UNILAB, Inc.Metro Manila
UNILAB, Inc.
DR-XY40082
Sep 22, 2031
ZudemDesloratadine
5 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's)
Rx
Lloyd Laboratories, Inc.Philippines
—
DRP-7775
Sep 13, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS CLARINEX Tablets are supplied as: Light blue, film-coated tablets embossed with “C5” containing 5 mg desloratadine. Light blue, film-coated tablets embossed with an elongated letters “S” and “P” on one side and plain on the other, containing 5 mg desloratadine. CLARINEX Tablets - 5 mg (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported. In such cases, stop CLARINEX at once and consider alternative treatments. (5.1) 5.1 Hypersensitivity Reactions Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported after administration of desloratadine. If such a reaction occurs, therapy with CLARINEX should be stopped and alternative treatment should be considered. [See Adverse Reactions (6.2).]

Drug interactions

Drug interactions (US label) US FDA label
7.1 Inhibitors of Cytochrome P450 3

7.1 Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]

7.2 Fluoxetine

7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]

7.3 Cimetidine

7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3).]

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following adverse reactions are discussed in greater detail in other sections of the label: Hypersensitivity reactions. [See Warnings and Precautions (5.1).] The most common adverse reactions (reported in ≥2% of adult and adolescent patients with allergic rhinitis and greater than placebo) were pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adults and Adolescents Allergic Rhinitis: In multiple-dose placebo-controlled trials, 2834 patients ages 12 years or older received CLARINEX Tablets at doses of 2.5 mg to 20 mg daily, of whom 1655 patients received the recommended daily dose of 5 mg.

In patients receiving 5 mg daily, the rate of adverse events was similar between CLARINEX and placebo-treated patients. The percent of patients who withdrew prematurely due to adverse events was 2.4% in the CLARINEX group and 2.6% in the placebo group. There were no serious adverse events in these trials in patients receiving desloratadine.

All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of CLARINEX Tablets (5 mg once daily), and that were more common with CLARINEX Tablets than placebo, are listed in Table 1. Table 1: Incidence of Adverse Events Reported by ≥2% of Adult and Adolescent Allergic Rhinitis Patients Receiving CLARINEX Tablets Adverse Event CLARINEX Tablets 5 mg (n=1655) Placebo (n=1652) Infections and Infestations Pharyngitis 4.1% 2.0% Nervous System Disorders Somnolence 2.1% 1.8% Gastrointestinal Disorders Dry Mouth 3.0% 1.9% Musculoskeletal and Connective Tissue Disorders Myalgia 2.1% 1.8% Reproductive System and Breast Disorders Dysmenorrhea 2.1% 1.6% General Disorders and Administration Site Conditions Fatigue 2.1% 1.2% The frequency and magnitude of laboratory and electrocardiographic abnormalities were similar in CLARINEX and placebo-treated patients.

There were no differences in adverse events for subgroups of patients as defined by gender, age, or race. Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic idiopathic urticaria, 211 patients ages 12 years or older received CLARINEX Tablets and 205 received placebo. Adverse events that were reported by greater than or equal to 2% of patients who received CLARINEX Tablets and that were more common with CLARINEX than placebo were (rates for CLARINEX and placebo, respectively): headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%), pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).

Pediatrics Two hundred and forty-six pediatric subjects 6 months to 11 years of age received CLARINEX Oral Solution for 15 days in three placebo-controlled clinical trials. Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1.0 mg once a day.

In subjects 6 to 11 years of age, no individual adverse event was reported by 2 percent or more of the subjects. In subjects 2 to 5 years of age, adverse events reported for CLARINEX and placebo in at least 2 percent of subjects receiving CLARINEX Oral Solution and at a frequency greater than placebo were fever (5.5%, 5.4%), urinary tract infection (3.6%, 0%) and varicella (3.6%, 0%).

In subjects 12 months to 23 months of age, adverse events reported for the CLARINEX product and placebo in at least 2 percent of subjects receiving CLARINEX Oral Solution and at a frequency greater than placebo were fever (16.9%, 12.9%), diarrhea (15.4%, 11.3%), upper respiratory tract infections (10.8%, 9.7%), coughing (10.8%, 6.5%), appetite increased (3.1%, 1.6%), emotional lability (3.1%, 0%), epistaxis (3.1%, 0%), parasitic infection (3.1%, 0%), pharyngitis (3.1%, 0%), rash maculopapular (3.1%, 0%). In subjects 6 months to 11 months of age, adverse events reported for CLARINEX and placebo in at least 2 percent of subjects receiving CLARINEX Oral Solution and at a frequency greater than placebo were upper respiratory tract infections (21.2%, 12.9%), diarrhea (19.7%, 8.1%), fever (12.1%, 1.6%), irritability (12.1%, 11.3%), coughing (10.6%, 9.7%), somnolence (9.1%, 8.1%), bronchitis (6.1%, 0%), otitis media (6.1%, 1.6%), vomiting (6.1%, 3.2%), anorexia (4.5%, 1.6%), pharyngitis (4.5%, 1.6%), insomnia (4.5%, 0%), rhinorrhea (4.5%, 3.2%), erythema (3.0%, 1.6%), and nausea (3.0%, 0%).

There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval. Only one of the 246 pediatric subjects receiving CLARINEX Oral Solution in the clinical trials discontinued treatment because of an adverse event.

6.2 Post-Marketing Experience

6.2 Post-Marketing Experience Because adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following spontaneous adverse events have been reported during the marketing of desloratadine: Cardiac disorders: tachycardia, palpitations Respiratory, thoracic and mediastinal disorders: dyspnea Skin and subcutaneous tissue disorders: rash, pruritus Nervous system disorders: psychomotor hyperactivity, movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures (reported in patients with and without a known seizure disorder) Immune system disorders: hypersensitivity reactions (such as urticaria, edema and anaphylaxis) Investigations: elevated liver enzymes including bilirubin Hepatobiliary disorders: hepatitis Metabolism and nutrition disorders: increased appetite

Adverse reaction frequency tables (US label) US FDA label
Table 1: Incidence of Adverse Events Reported by ≥2% of Adult and Adolescent Allergic Rhinitis Patients Receiving CLARINEX Tablets
Adverse EventCLARINEX Tablets 5 mg (n=1655)Placebo (n=1652)
Infections and Infestations
Pharyngitis4.1%2.0%
Nervous System Disorders
Somnolence2.1%1.8%
Gastrointestinal Disorders
Dry Mouth3.0%1.9%
Musculoskeletal and Connective Tissue Disorders
Myalgia2.1%1.8%
Reproductive System and Breast Disorders
Dysmenorrhea2.1%1.6%
General Disorders and Administration Site Conditions
Fatigue2.1%1.2%

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary The limited available data with CLARINEX in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are no adequate and well-controlled studies in pregnant women. Desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (AUC)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (RHD) of 5 mg/day.

Desloratadine given during organogenesis to pregnant rabbits was not teratogenic at the AUC-based exposures of desloratadine approximately 230 times that at the RHD. Desloratadine given to pregnant rats during organogenesis through lactation resulted in reduced body weight and slow righting reflex of F 1 pups at the summed AUC-based exposures of desloratadine and its metabolite approximately 70 times or greater than that at the RHD [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Desloratadine was given orally during organogenesis to pregnant rats at doses of 6, 24 and 48 mg/kg/day (approximately 50, 200 and 320 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD).

No fetal malformations were present. Reduced fetal weights and skeletal variations noted at doses of 24 and 48 mg/kg/day were likely secondary to the maternal toxicities of reduced body weight gain and food consumption observed at the same doses. Desloratadine was also given orally during organogenesis to pregnant rabbits at doses of 15, 30 and 60 mg/kg/day (approximately 30, 70 and 230 times the AUC-based exposure of desloratadine at the RHD).

No adverse effects to the fetus were noted. Reduced maternal body weight gain was noted in rabbits at 60 mg/kg/day. In a peri- and post-natal development study, desloratadine was given to rats orally during the peri-natal (Gestation Day 6) through lactation periods (Postpartum Day 21) at doses of 3, 9 and 18 mg/kg/day. Reduced body weight and slow righting reflex were reported in F 1 pups at doses of 9 mg/kg/day or greater (approximately 70 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD).

Desloratadine had no effect on F 1 pup development at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Maternal toxicities including reduced body weight gain and food consumption were noted at 18 mg/kg/day for F 0 dams. F 1 offspring were subsequently mated and there was no developmental toxicity for F 2 pups observed.

Mechanism of action

12.1 Mechanism of Action Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2–3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited histamine release from human mast cells in vitro.

Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Wheal and Flare: Human histamine skin wheal studies following single and repeated 5-mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the desloratadine 5-mg group over the 28-day treatment period.

The clinical relevance of histamine wheal skin testing is unknown. Effects on QT c: Single daily doses of 45 mg were given to normal male and female volunteers for 10 days. All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In CLARINEX-treated subjects, there was an increase in mean heart rate of 9.2 bpm relative to placebo.

The QT interval was corrected for heart rate (QT c) by both the Bazett and Fridericia methods. Using the QT c (Bazett) there was a mean increase of 8.1 msec in CLARINEX-treated subjects relative to placebo. Using QT c (Fridericia) there was a mean increase of 0.4 msec in CLARINEX-treated subjects relative to placebo. No clinically relevant adverse events were reported.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours).

Elimination The mean plasma elimination half-life of desloratadine was approximately 27 hours.

The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency.

Analysis of plasma 3-hydroxydesloratadine showed similar T max and half-life values compared to desloratadine.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5-mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively. Neither food nor grapefruit juice had an effect on the bioavailability (C max and AUC) of desloratadine.

The pharmacokinetic profile of CLARINEX Oral Solution was evaluated in a three-way crossover study in 30 adult volunteers. A single dose of 10 mL of CLARINEX Oral Solution containing 5 mg of desloratadine was bioequivalent to a single dose of 5-mg CLARINEX Tablet. Food had no effect on the bioavailability (AUC and C max) of CLARINEX Oral Solution.

The pharmacokinetic profile of CLARINEX RediTabs Tablets was evaluated in a three-way crossover study in 24 adult volunteers. A single CLARINEX RediTabs Tablet containing 5 mg of desloratadine was bioequivalent to a single 5-mg CLARINEX RediTabs Tablet (original formulation) for both desloratadine and 3-hydroxydesloratadine.

Food and water had no effect on the bioavailability (AUC and C max) of CLARINEX RediTabs Tablets. Distribution Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89% bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function.

Metabolism Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine.

In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1575 subjects aged 6 to 11 years, and 1196 subjects aged 12 to 70 years.

There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1,462) and Hispanics (2%, n=1,063). The median exposure (AUC) to desloratadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers.

Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidose clinical safety studies, where metabolizer status was identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with CLARINEX Oral Solution for 15–35 days.

In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out. Elimination The mean plasma elimination half-life of desloratadine was approximately 27 hours.

C max and AUC values increased in a dose proportional manner following single oral doses between 5 and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human mass balance study documented a recovery of approximately 87% of the 14 C-desloratadine dose, which was equally distributed in urine and feces as metabolic products.

Analysis of plasma 3-hydroxydesloratadine showed similar T max and half-life values compared to desloratadine.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Clarinex · Organon LLC [US FDA-approved label, version 6, May 17, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c671342e-69a2-4ca5-abc2-8166ed4240d4
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .